Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk
Cardiovascular European Research Center · Hôpital de la Tour · +34 more institutions
Abstract
Identification and management of patients at high bleeding risk undergoing percutaneous coronary intervention are of major importance, but a lack of standardization in defining this population limits trial design, data interpretation, and clinical decision-making. The Academic Research Consortium for High Bleeding Risk (ARC-HBR) is a collaboration among leading research organizations, regulatory authorities, and physician-scientists from the United States, Asia, and Europe focusing on percutaneous coronary intervention-related bleeding. Two meetings of the 31-member consortium were held in Washington, DC, in April 2018 and in Paris, France, in October 2018. These meetings were organized by the Cardiovascular…
Citation impact
- FWCI
- 44.69
- Percentile
- 100%
- References
- 150
Authors
34- PUPhilip UrbanCorresponding
Cardiovascular European Research Center, Hôpital de la Tour
- RMRoxana Mehran
Icahn School of Medicine at Mount Sinai
- RCRóisín Colleran
Deutsches Herzzentrum München, Technical University of Munich
- DJDominick J. Angiolillo
University of Florida, Florida College
- RARobert A. Byrne
Deutsches Herzzentrum München, Technical University of Munich
Topics & keywords
- Medicine
- Percutaneous coronary intervention
- Major bleeding
- MEDLINE
- Severe bleeding
- Surgery
- Internal medicine
- Myocardial infarction
Funding
- AAmgen
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- GGlaxoSmithKline
- SSanofi
- MMedtronic
- ELEdwards Lifesciences
- BBB. Braun Melsungen
- CFChiesi Farmaceutici
- UOUniversity of Florida
- CBCSL Behring
- BSBoston Scientific Corporation
- MMedicure
- CMCook Medical
- ACAmarin Corporation
- CUChiesi USA
- AAbiomed
- DDaiichi-Sankyo
- NNNovo Nordisk
- BBiotronik
- TTerumo
- BIBiosensors International Group
- SServier
- IPIdorsia Pharmaceuticals
- NINational Institutes of HealthAwards: HG007269, U01 HG007269, TR000064
- AVAbbott Vascular
- NCNational Center for Advancing Translational SciencesAwards: U01 HG007269, TR000064
- CCordis
- BWBiosense Webster
- JPJanssen Pharmaceuticals
- DSDaiichi Sankyo Europe